Vaxcyte Future Growth
Future criteria checks 0/6
Vaxcyte's earnings are forecast to decline at 4.5% per annum while its annual revenue is expected to grow at 89.1% per year. EPS is expected to decline by 2.2% per annum.
Key information
-4.5%
Earnings growth rate
-2.2%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 89.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 06 Dec 2024 |
Recent future growth updates
Recent updates
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Dec 08Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Sep 06We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27Vaxcyte appoints new CBO, CMO
Oct 11Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate
Jul 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 21 | -654 | -516 | -820 | 7 |
12/31/2025 | N/A | -608 | -544 | -543 | 8 |
12/31/2024 | N/A | -486 | -509 | -331 | 8 |
9/30/2024 | N/A | -508 | -616 | -470 | N/A |
6/30/2024 | N/A | -497 | -582 | -467 | N/A |
3/31/2024 | N/A | -437 | -483 | -408 | N/A |
12/31/2023 | N/A | -402 | -365 | -297 | N/A |
9/30/2023 | N/A | -300 | -245 | -233 | N/A |
6/30/2023 | N/A | -265 | -220 | -214 | N/A |
3/31/2023 | N/A | -245 | -199 | -191 | N/A |
12/31/2022 | N/A | -223 | -176 | -171 | N/A |
9/30/2022 | N/A | -174 | -163 | -156 | N/A |
6/30/2022 | N/A | -143 | -153 | -146 | N/A |
3/31/2022 | N/A | -118 | -144 | -136 | N/A |
12/31/2021 | N/A | -100 | -128 | -121 | N/A |
9/30/2021 | N/A | -92 | -87 | -81 | N/A |
6/30/2021 | N/A | -87 | -70 | -66 | N/A |
3/31/2021 | N/A | -83 | -48 | -46 | N/A |
12/31/2020 | N/A | -89 | -48 | -47 | N/A |
9/30/2020 | N/A | -83 | -52 | -50 | N/A |
6/30/2020 | N/A | -73 | -48 | -47 | N/A |
3/31/2020 | N/A | -64 | -53 | -51 | N/A |
12/31/2019 | N/A | -50 | -48 | -47 | N/A |
12/31/2018 | N/A | -29 | -32 | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCVX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PCVX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PCVX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PCVX is forecast to have no revenue next year.
High Growth Revenue: PCVX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PCVX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 15:07 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxcyte, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Matthew Gerberry | BofA Global Research |
Thomas Shrader | BTIG |
Louise Chen | Cantor Fitzgerald & Co. |